35.43 USD
+0.36 (+1.03%)
35.43 USD
0 (0%)
IBEX gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 86 industry peers in the IT Services industry. IBEX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. An interesting combination arises when we look at growth and value: IBEX is growing strongly while it also seems undervalued. With these ratings, IBEX could be worth investigating further for value and growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year IBEX was profitable.
In the past year IBEX had a positive cash flow from operations.
In the past 5 years IBEX has always been profitable.
In the past 5 years IBEX always reported a positive cash flow from operatings.
1.2 Ratios
IBEX has a Return On Assets of 13.49%. This is amongst the best in the industry. IBEX outperforms 93.02% of its industry peers.
Looking at the Return On Equity, with a value of 27.45%, IBEX belongs to the top of the industry, outperforming 89.53% of the companies in the same industry.
With an excellent Return On Invested Capital value of 20.43%, IBEX belongs to the best of the industry, outperforming 94.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.49% | ||
| ROE | 27.45% | ||
| ROIC | 20.43% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IBEX's Profit Margin of 6.60% is fine compared to the rest of the industry. IBEX outperforms 68.60% of its industry peers.
In the last couple of years the Profit Margin of IBEX has grown nicely.
The Operating Margin of IBEX (8.71%) is better than 66.28% of its industry peers.
In the last couple of years the Operating Margin of IBEX has grown nicely.
IBEX has a Gross Margin of 30.91%. This is comparable to the rest of the industry: IBEX outperforms 44.19% of its industry peers.
IBEX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.71% | ||
| PM (TTM) | 6.6% | ||
| GM | 30.91% |
OM growth 3Y27.75%
OM growth 5Y12.6%
PM growth 3Y14.82%
PM growth 5Y27.95%
GM growth 3Y0.55%
GM growth 5YN/A
2. Health
2.1 Basic Checks
IBEX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
IBEX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
IBEX has an Altman-Z score of 5.07. This indicates that IBEX is financially healthy and has little risk of bankruptcy at the moment.
IBEX has a better Altman-Z score (5.07) than 75.58% of its industry peers.
IBEX has a debt to FCF ratio of 0.06. This is a very positive value and a sign of high solvency as it would only need 0.06 years to pay back of all of its debts.
The Debt to FCF ratio of IBEX (0.06) is better than 91.86% of its industry peers.
IBEX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.01, IBEX belongs to the top of the industry, outperforming 82.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.06 | ||
| Altman-Z | 5.07 |
ROIC/WACC2.28
WACC8.97%
2.3 Liquidity
IBEX has a Current Ratio of 1.82. This is a normal value and indicates that IBEX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.82, IBEX is in line with its industry, outperforming 55.81% of the companies in the same industry.
A Quick Ratio of 1.82 indicates that IBEX should not have too much problems paying its short term obligations.
IBEX has a Quick ratio (1.82) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.82 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 41.96% over the past year.
Measured over the past years, IBEX shows a very strong growth in Earnings Per Share. The EPS has been growing by 41.04% on average per year.
Looking at the last year, IBEX shows a quite strong growth in Revenue. The Revenue has grown by 9.77% in the last year.
Measured over the past years, IBEX shows a small growth in Revenue. The Revenue has been growing by 6.62% on average per year.
EPS 1Y (TTM)41.96%
EPS 3Y28.16%
EPS 5Y41.04%
EPS Q2Q%73.08%
Revenue 1Y (TTM)9.77%
Revenue growth 3Y4.24%
Revenue growth 5Y6.62%
Sales Q2Q%16.55%
3.2 Future
IBEX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.11% yearly.
IBEX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.28% yearly.
EPS Next Y16.57%
EPS Next 2Y12.11%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year10.8%
Revenue Next 2Y8.28%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 11.14, the valuation of IBEX can be described as reasonable.
Compared to the rest of the industry, the Price/Earnings ratio of IBEX indicates a rather cheap valuation: IBEX is cheaper than 87.21% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 25.98, IBEX is valued rather cheaply.
The Price/Forward Earnings ratio is 10.07, which indicates a very decent valuation of IBEX.
Based on the Price/Forward Earnings ratio, IBEX is valued cheaper than 88.37% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 35.79. IBEX is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.14 | ||
| Fwd PE | 10.07 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IBEX is valued cheaply inside the industry as 88.37% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, IBEX is valued a bit cheaper than 65.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.29 | ||
| EV/EBITDA | 6.88 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of IBEX may justify a higher PE ratio.
IBEX's earnings are expected to grow with 12.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.67
PEG (5Y)0.27
EPS Next 2Y12.11%
EPS Next 3YN/A
5. Dividend
5.1 Amount
IBEX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
35.43
+0.36 (+1.03%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)
Earnings (Next)
Inst Owners94.9%
Inst Owner Change-3.89%
Ins Owners8.95%
Ins Owner Change-3.38%
Market Cap471.93M
Revenue(TTM)558.27M
Net Income(TTM)36.86M
Analysts45.71
Price Target39.27 (10.84%)
Short Float %1.24%
Short Ratio0.9
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.37%
Min EPS beat(2)10.89%
Max EPS beat(2)21.85%
EPS beat(4)4
Avg EPS beat(4)13.65%
Min EPS beat(4)7.33%
Max EPS beat(4)21.85%
EPS beat(8)7
Avg EPS beat(8)11.1%
EPS beat(12)10
Avg EPS beat(12)14.9%
EPS beat(16)11
Avg EPS beat(16)6.92%
Revenue beat(2)2
Avg Revenue beat(2)6.82%
Min Revenue beat(2)5.12%
Max Revenue beat(2)8.52%
Revenue beat(4)4
Avg Revenue beat(4)4.42%
Min Revenue beat(4)1.58%
Max Revenue beat(4)8.52%
Revenue beat(8)4
Avg Revenue beat(8)1.31%
Revenue beat(12)4
Avg Revenue beat(12)-0.58%
Revenue beat(16)6
Avg Revenue beat(16)-0.56%
PT rev (1m)0%
PT rev (3m)26.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.55%
EPS NY rev (1m)0%
EPS NY rev (3m)4.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)5.66%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.72%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.14 | ||
| Fwd PE | 10.07 | ||
| P/S | 0.85 | ||
| P/FCF | 17.29 | ||
| P/OCF | 10.33 | ||
| P/B | 3.51 | ||
| P/tB | 3.87 | ||
| EV/EBITDA | 6.88 |
EPS(TTM)3.18
EY8.98%
EPS(NY)3.52
Fwd EY9.93%
FCF(TTM)2.05
FCFY5.78%
OCF(TTM)3.43
OCFY9.68%
SpS41.91
BVpS10.08
TBVpS9.16
PEG (NY)0.67
PEG (5Y)0.27
Graham Number26.86
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.49% | ||
| ROE | 27.45% | ||
| ROCE | 25.17% | ||
| ROIC | 20.43% | ||
| ROICexc | 22.19% | ||
| ROICexgc | 23.83% | ||
| OM | 8.71% | ||
| PM (TTM) | 6.6% | ||
| GM | 30.91% | ||
| FCFM | 4.89% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y27.75%
OM growth 5Y12.6%
PM growth 3Y14.82%
PM growth 5Y27.95%
GM growth 3Y0.55%
GM growth 5YN/A
F-Score8
Asset Turnover2.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.06 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 106.63% | ||
| Cap/Sales | 3.29% | ||
| Interest Coverage | 29.77 | ||
| Cash Conversion | 69.33% | ||
| Profit Quality | 74.04% | ||
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.82 | ||
| Altman-Z | 5.07 |
F-Score8
WACC8.97%
ROIC/WACC2.28
Cap/Depr(3y)83.97%
Cap/Depr(5y)108.52%
Cap/Sales(3y)2.89%
Cap/Sales(5y)3.72%
Profit Quality(3y)75.63%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.96%
EPS 3Y28.16%
EPS 5Y41.04%
EPS Q2Q%73.08%
EPS Next Y16.57%
EPS Next 2Y12.11%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)9.77%
Revenue growth 3Y4.24%
Revenue growth 5Y6.62%
Sales Q2Q%16.55%
Revenue Next Year10.8%
Revenue Next 2Y8.28%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.91%
EBIT growth 3Y33.16%
EBIT growth 5Y20.06%
EBIT Next Year66.44%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.92%
FCF growth 3Y24.66%
FCF growth 5Y-10.09%
OCF growth 1Y27.21%
OCF growth 3Y4.51%
OCF growth 5Y-2.46%
IBEX LTD / IBEX FAQ
Can you provide the ChartMill fundamental rating for IBEX LTD?
ChartMill assigns a fundamental rating of 7 / 10 to IBEX.
Can you provide the valuation status for IBEX LTD?
ChartMill assigns a valuation rating of 8 / 10 to IBEX LTD (IBEX). This can be considered as Undervalued.
What is the profitability of IBEX stock?
IBEX LTD (IBEX) has a profitability rating of 7 / 10.
Can you provide the financial health for IBEX stock?
The financial health rating of IBEX LTD (IBEX) is 7 / 10.
Can you provide the expected EPS growth for IBEX stock?
The Earnings per Share (EPS) of IBEX LTD (IBEX) is expected to grow by 16.57% in the next year.